February 6, 2020
VIA EDGAR
Chris Edwards
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
| Re: | Oramed Pharmaceuticals Inc. |
| Registration Statement on Form S-3 | |
| File No. 333-236194 |
Dear Sir or Madam:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Oramed Pharmaceuticals Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 2:00 p.m., Eastern Time, on February 10, 2020, or as soon as practicable thereafter.
The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Howard E. Berkenblit of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP at (617) 338-2979 and that such effectiveness also be confirmed in writing.
| Very truly yours, | |||
| Oramed Pharmaceuticals Inc. | |||
| By: | /s/ Avraham Gabay | ||
| Name: | Avraham Gabay | ||
| Title: | Chief Financial Officer | ||